Biohaven 1 article

Biohaven brings neurological and immunologic therapeutics and extracellular protein degradation into the same corporate research profile, characteristic of a neurology and immunology biopharmaceutical company. MoDE protein degrader platform complements TRAP autoantibody degrader platform at Biohaven, while brain-penetrant TYK2 JAK1 inhibition provides a separate mechanistic anchor for the company. Biohaven is therefore matched through a combination of mechanisms including myostatin activin pathway inhibition, while individual products remain independently tagged.